Consequently, to develop therapies targeting FGF21 production induced by GLN for cognitive disorders, enhancing GLN’s bioavailability through dosage optimization and alternative administration methods is imperative to maximize its effects. The gene discussed is FGF21; the disease is cognitive disorder.